Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
Adolescent
Adult
Aged
Aged, 80 and over
Allografts
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bone Marrow
/ chemistry
Combined Modality Therapy
Cytarabine
/ administration & dosage
Disease-Free Survival
Female
Gene Dosage
Gene Expression Regulation, Neoplastic
Humans
Leukemia, Myeloid, Acute
/ diagnosis
Male
Middle Aged
Neoplasm Proteins
/ biosynthesis
Peripheral Blood Stem Cell Transplantation
Polymerase Chain Reaction
/ methods
Prognosis
Proto-Oncogene Proteins c-abl
/ genetics
Trans-Activators
/ biosynthesis
Treatment Outcome
Tumor Suppressor Proteins
/ biosynthesis
Young Adult
Acute myeloid leukemia
Allogeneic stem cell transplantation
BAALC
MN1
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
06
07
2020
accepted:
24
08
2020
pubmed:
31
8
2020
medline:
2
10
2020
entrez:
31
8
2020
Statut:
ppublish
Résumé
For most acute myeloid leukemia (AML) patients, an allogeneic hematopoietic stem cell transplantation (HSCT) offers the highest chance of sustained remissions and long-term survival. At diagnosis, high expression of the AML-associated genes BAALC (brain and acute leukemia, cytoplasmic) and MN1 (meningioma-1) were repeatedly linked to inferior outcomes in patients consolidated with chemotherapy while data for patients receiving HSCT remain limited. Using clinically applicable digital droplet PCR assays, we analyzed the diagnostic BAALC/ABL1 and MN1/ABL1 copy numbers in 302 AML patients. High BAALC/ABL1 and MN1/ABL1 copy numbers associated with common adverse prognostic factors at diagnosis. However, while high diagnostic copy numbers of both genes associated with shorter event free survival (EFS) and overall survival (OS) in patients receiving chemotherapy, there was no prognostic impact in patients undergoing HSCT. Our data suggests that the adverse prognostic impact of high BAALC and MN1 expression are mitigated by allogeneic HSCT. But preHSCT BAALC/ABL1 and MN1/ABL1 assessed in remission prior to HSCT remained prognosticators for EFS and OS independent of the diagnostic expression status. Whether allogeneic HSCT may improve survival for AML patients with high diagnostic BAALC or MN1 expression should be investigated prospectively and may improve informed decisions towards individualized consolidation options in AML.
Identifiants
pubmed: 32862286
doi: 10.1007/s00277-020-04235-8
pii: 10.1007/s00277-020-04235-8
pmc: PMC7481166
doi:
Substances chimiques
BAALC protein, human
0
MN1 protein, human
0
Neoplasm Proteins
0
Trans-Activators
0
Tumor Suppressor Proteins
0
Cytarabine
04079A1RDZ
ABL1 protein, human
EC 2.7.10.2
Proto-Oncogene Proteins c-abl
EC 2.7.10.2
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2417-2427Subventions
Organisme : José Carreras Leukämie-Stiftung (DE)
ID : 04R/2016
Organisme : José Carreras Leukämie-Stiftung
ID : PS15/05
Organisme : Novartis Pharma
ID : HRYD-030
Références
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447
doi: 10.1182/blood-2016-08-733196
McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus- tumor effects. Blood 97:3390–3400
doi: 10.1182/blood.V97.11.3390
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555–562
doi: 10.1182/blood.V75.3.555.555
Heuser M, Beutel G, Krauter J, Döhner K, von Neuhoff N, Schlegelberger B et al (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108:3898–3905
doi: 10.1182/blood-2006-04-014845
Heuser M, Berg T, Kuchenbauer F, Lai CK, Park G, Fung S et al (2012) Functional role of BAALC in leukemogenesis. Leukemia 26:532–536
doi: 10.1038/leu.2011.228
Baldus CD, Tanner SM, Kusewittb DF, Liyanarachchi S, Choi C, Caligiuri MA et al (2003) BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol 31:1051–1056
pubmed: 14585369
Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K et al (2001) BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A 98:13901–13906
doi: 10.1073/pnas.241525498
Lekanne Deprez RH, Groen NA, van Biezen NA, Hagemeijer A, van Drunen E, Koper JW et al (1991) A t(4;22) in a meningioma points to the localization of a putative tumor-suppressor gene. Am J Hum Genet 48:783–790
pubmed: 2014801
pmcid: 1682947
Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K et al (2008) High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111:5371–5379
doi: 10.1182/blood-2007-11-124958
Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB et al (2010) BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 116:5660–5669
doi: 10.1182/blood-2010-06-290536
Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrózek K, Maharry K et al (2011) Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 118:4188–4198
doi: 10.1182/blood-2011-06-357764
Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A et al (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 27:5031–5038
doi: 10.1200/JCO.2008.20.5328
Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P et al (2009) Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 27:3198–3204
doi: 10.1200/JCO.2008.20.6110
Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G et al (2003) BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood 102:1613–1618
doi: 10.1182/blood-2003-02-0359
Jentzsch M, Bill M, Grimm J, Schulz J, Goldmann K, Beinicke S et al (2017) High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. Oncotarget. 8:87944–87954
doi: 10.18632/oncotarget.21322
Jentzsch M, Bill M, Grimm J, Schulz J, Beinicke S, Häntschel J et al (2019) Prognostic impact of blood MN1 copy numbers before allogeneic stem cell transplantation in patients with acute myeloid leukemia. HemaSphere 3:e167
doi: 10.1097/HS9.0000000000000167
Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C et al (2014) BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia. Blood Cancer J 4:e173
doi: 10.1038/bcj.2013.71
Najima Y, Ohashi K, Kawamura M, Onozuka Y, Yamaguchi T, Akiyama H et al (2010) Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia. J Hematol 91:636–645
Carturan S, Petiti J, Rosso V, Calabrese C, Signorino E, Bot-Sartor G et al (2016) Variable but consistent pattern of meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. Oncotarget 7:74082–74096
doi: 10.18632/oncotarget.12269
Zhang J, Shi J, Zhang G, Zhang X, Yang X, Yang S et al (2018) BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol 97(8):1391–1397
doi: 10.1007/s00277-018-3331-8
Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ et al (2013) Absolute quantification by droplet digital PCR versus analog real- time PCR. Nat Methods 10:1003–1005
doi: 10.1038/nmeth.2633
Jentzsch M, Bill M, Grimm J, Schulz J, Schuhmann L, Brauer D et al (2020) High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population. Haematologica. https://doi.org/10.3324/haematol.2019.229260
Bill M, Jentzsch M, Grimm J, Schubert K, Lange T, Cross M et al (2017) Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning. Bone Marrow Transplant 52:932–935
doi: 10.1038/bmt.2017.42
Grimm J, Bill M, Jentzsch M, Beinicke S, Häntschel J, Goldmann K et al (2019) Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. Bone Marrow Transplant 54:1189–1197
doi: 10.1038/s41409-018-0413-0
R Core Team (2017) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna http://www.R-project.org
Breems DA, van Putten WLJ, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH et al (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26:4791–4797
doi: 10.1200/JCO.2008.16.0259
Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M et al (2005) Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 11:1416–1424
doi: 10.1158/1078-0432.CCR-04-1552
Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G (2006) BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol 24:790–797
doi: 10.1200/JCO.2005.01.6253
Brand J, van Vliet MH, de Best L, Valk PJ, Viëtor HE, Löwenberg B et al (2013) A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC. Exp Hematol Oncol 2:7
doi: 10.1186/2162-3619-2-7
Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV et al (2010) BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann Hematol 89:453–458
doi: 10.1007/s00277-009-0864-x
Damiani D, Tiribelli M, Franzoni A, Michelutti A, Fabbro D, Cavallin M et al (2013) BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients. Am J Hematol 88:848–852
doi: 10.1002/ajh.23516
Haferlach C, Kern W, Schindela S, Kohlmann A, Alpermann T, Schnittger S et al (2012) Gene expression of BAALC, CDKNIB, ERG and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Genes Chromosom Cancer 51:257–265
doi: 10.1002/gcc.20950
Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS et al (2014) Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. Leuk Lymphoma 55:110–120
doi: 10.3109/10428194.2013.800869
Liu T, Jankovic D, Brault L, Ehret S, Baty F, Stavropoulou V et al (2010) Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. Leukemia 24:601–512
doi: 10.1038/leu.2009.272
Hills RK, Castaigne S, Appelbaum FR et al (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15(9):986–996
doi: 10.1016/S1470-2045(14)70281-5
Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M et al (2016) Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD. Biol Blood Marrow Transplant 22:462–469
doi: 10.1016/j.bbmt.2015.10.023
Grimm J, Jentzsch M, Bill M et al (2020) Prognostic Impact of the European LeukemiaNet 2017 risk classification in acute myeloid leukemia patients receiving allogeneic transplantation. Blood Adv In Press
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y et al (2016) Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease–based definition of complete remission? J Clin Oncol 34:329–336
doi: 10.1200/JCO.2015.63.3826
Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB et al (2016) Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 30:1456–1464
doi: 10.1038/leu.2016.46
Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C et al (2018) Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 132:1703–1713
doi: 10.1182/blood-2018-02-829911
Bill M, Grimm J, Jentzsch M, Kloss L, Goldmann K, Schulz J et al (2018) Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Ann Hematol 97:1757–1765
doi: 10.1007/s00277-018-3373-y